Alone, or in combination with other therapies, Immuno-Oncology (I-O) appears currently as one of the most promising research fields to fight cancer. Nevertheless, developing breakthrough therapies to fully harness the immune system to fight diseased cells remain quite challenging.

To help researchers solve these hurdles, we have selected a complete offer of innovative and robust reagents and services. In this post, I wanted to highlight 6 Immuno-Oncology “must-haves” to facilitate your R&D projects.

Based on a novel variety of Magnetic Nanoparticles, ElementZero have just launched a unique technology, allowing specific capture and enrichment of a broad variety of viral RNA (SARS-CoV-2, HIV, Ebola….), or any of your specific RNA or DNA targets. Discover these new products, now available at in Europe through tebu-bio.

Researchers have shown that proteases are actively used by SARS-CoV-2 for it’s entry and replication into human cells. To support research on this topic, tebu-bio provides a full range of screening kits to identify inhibitory compounds directed against these human and viral proteases .

To better understand the mechanism of SARS-CoV-2 cell entry, BPS Bioscience have developed 3 new pseudotyped lentiviruses, allowing you to study the interaction between the coronavirus Spike protein and the human ACE2 protein in a physiologically relevant context.